Venn Life Sciences Share Discussion Threads

[cocker] 30/8/2016 10:52

Very hard to read advfn trades as quite often mine are shown wrong. However, even if they were all buys last Friday,then someone is waiting in the wings with a sell order which will appear sooner or later.

[investordave] 30/8/2016 10:36

GHF. If you don't mind me asking, how do you know they were all buys?

[glasshalfull] 30/8/2016 10:27

Morning all,

Interesting to read all the speculation concerning the 50k trades on Friday.

Courtesy to inform that they were all buys. Pleased to get the opportunity to top up on the dip. Just goes to show that one should tread with caution when speculating on trades.

I've also made further top ups this morning...so that should save further speculation :-)

Regards,
GHF

[robbiereliable] 29/8/2016 21:12

Thanks yump, I was worried this was a tulip producer. Fighting the urge to escape this share. I was made up when it jumped after I bought it, but because I was an idiot, the jump only covered the spread. Doh! Now it's dropped again, getting nervous but will press on for now. Does anyone have an idea of when the company will make money on the new contract they have won?

[chadders] 29/8/2016 16:42

Fwiw, I reckon the 50000 at 27.5 was a buy. The 15000 at 27.1 was mine and it was a buy. Not sure why the dip but it was the reason I topped up.

[ali47fish] 27/8/2016 15:25

love the way you explain this yump- and it seems to make sense!

[yump] 27/8/2016 14:45

The dip is meaningless. Look how many times its happened in the past. 10% jumps and dips clearly the norm - usually its because volumes are small and MM's don't want too little or too much stock on their hands, given there's not much trade generally. Small stock etc. etc.

If it was a trader's darling (eg. overhyped with a big story but no decent results and open to speculation) then there would be much higher volume and smaller % moves.

Venn is imo what you might call a proper investment stock in the older sense of 'investment', a decent growing business, not a tulip producer.

[investordave] 27/8/2016 13:11

I recognise that everyone has their own reasons for selling but why do so just before what are expected to be a great set of results? Makes no sense to me. Still also strikes me as bizarre that a sale of just £15K of shares can cause such a big dip in the share price

[cocker] 27/8/2016 09:34

3x 50k sells. Ok , like yesterday we might see some downward pressure at times. However, this only offers opportunities for those wanting to either enter or top up. Venn is an absolute steal under 40 p, it's just a matter of when & not if it makes it.

[investordave] 27/8/2016 09:27

Would anyone like to speculate on what caused the large dip in the share price towards the end of the day yesterday. It certainly took me by surprise. I hope Techinvest haven't sold up.

[harry vederci] 26/8/2016 15:56

rude not to at that price

buy at 27.1 !

[cocker] 26/8/2016 14:55

Always thought end of month!

[cocker] 26/8/2016 13:56

Should get a decent mention in Techinvest tomorrow. Perhaps a subscriber could update us all!

[rivaldo] 24/8/2016 07:09

RNS - interims will be on 28th September:



Great to see that as well as a briefing for analysts, there's another presentation which all investors can attend in the evening. VENN are evidently one of the more progressive companies around.

[paleje] 08/8/2016 15:26

I wondered about that too, they don't mention it at all but in their June note they state a target of 43p which definitely didn't include anything for the Innoven spin-off. The link for it is now directed at the 03 Aug note but the content was pasted on here and I've copied it below, the last para is the one.

Would they have added 5p based on that last contract announcement, I wouldn't have thought so but then again it plus the possible Innoven spin-off would surely come to more than that. I'm veering towards the 'more to come' side.


June article:-

This was on 3i's website, numbers as mentioned above but I hadn't seen the last para before about the share price, if it's already been posted sorry:-

REISSUED 2015E is replaced with 2015A – ALL NUMBERS REMAIN UNCHANGED. The growing European Contract Research Organisation (CRO) has reported final results for the year to December 2015. Revenue growth of 135% to €11.47m exceeded our already upgraded revenue forecast of €11.2m. Underlying Group EBITDA showed a €1.9m swing from a €1.53m loss to a profit of €0.39m vs our forecast of €0.49m. We attribute this shortfall to development costs at Innovenn. EBITDA attributable to the CRO business was €0.8m. Depreciation and amortisation charges were €0.46m vs our expectation of €0.22m. The company underwent a step change in scale via the acquisition of Kinesis in Q4 which we understand contributed circa 12% to FY revenues owing to the short period under ownership. With €4.4m revenue booked in Q1 vs €2m in Q1 2015, and the commencement of successful cross selling of services across the enlarged client base, we have confidence in our €17m FY2016 revenue forecast, growth of 48% which we forecast to result in a more than fourfold jump in underlying EBITDA to €1.75m and an adjusted profit of €1.6m equating to adjusted EPS of €0.027c reaching €0.032c by 2018. There is however scope for faster revenue growth and greater margin progression. The company finished the year with cash balances of €3.8m, a strong base from which to negotiate potential acquisition opportunities in Central and Eastern Europe that are being explored as well as selective organic expansion into other areas. Innovenn, Venn’s innovation division, has made good progress with both Labskin and Clarogel through their development phases. These are currently being commercialised.

Venn intends to reposition this business such that it has an independent footing, its own source of funding and a value that can be clearly established. The shares are on an adjusted PE multiple of 12.4x for 2016. Innovenn made an EBITDA loss this year of €0.44m. If we simply add back a similar figure to our forecast for next year this puts the company on a sub 10x PE rating, as if it were the CRO business on its own. Even at a share price of 43p (74% above the current share price) this rating is only at 16x these pro-forma earnings broadly in line at the sector, and does not take into account any separate value for Innovenn which has two differentiated market ready integumentary products targeting growing markets.

[rivaldo] 08/8/2016 12:26

Cheers paleje, makes good reading.

A 48p share price would be nice "in line with the broader healthcare sector", though even this doesn't appear to include any upside from an Innovenn spin-off.

[paleje] 05/8/2016 16:03

Hybridan's updated note is below, they reckon 48p would bring it in line with sector peers:-

[nfs] 05/8/2016 11:19

Hmm the quality is undermined somewhat by the 1.2 * forward earnings ,think they meant to say revenues

[mulligut] 04/8/2016 13:02

Rivaldo, Research Analyst post is very positive. Pity you cannot obtain source.

[paleje] 04/8/2016 08:37

Thanks Rivaldo, I like TR he gets on with things no BS.

Beaufort reissued their speculative buy note this morning with the share price at 30p, no target given. I only mention it because it's odd imo, they don't act for the co (thank goodness) so why.

[rivaldo] 04/8/2016 08:15

New 5 minute interview with the CEO about the contract wins FYI:

http ://www.proactiveinvestors.co.uk/companies/stocktube/5354/new-contract-build-global-footprint-says-venn-life-sciences-holdings-plc-ceo-5354.html?utm_source=Sign-Up.to&utm_medium=email&utm_campaign=7163-355215-PROACTIVITY+-+Techfinancials+advancing+with+confidence

"New contract build global footprint, says Venn Life Sciences Holdings plc CEO
13:26 03 Aug 2016

Venn Life Sciences Holdings plc (LON:VENN) says the newly awarded €2.8mln contract allows the group to “build a proper international footprint”. The contract is with a European biotech group to carry out a phase II trial.

Chief executive Tony Richardson says “it’s the kind of business we’ve really been pursuing.” “It’s a good up-and-coming European bio-tech client operating across many countries,” he adds.

Venn hails the deal and says vendor qualification is a significant milestone for its Interactive Response Technology and represents an exciting opportunity to grow a global account.

“The deal allows us to build a proper international footprint,” says Richardson.
“It’s an exciting area to be working in and fits really well with current capabilities.”

The trial is for an immunotherapeutic treatment for Multiple Sclerosis, involving patients in six countries across Europe and starts in October."

[pentangle] 03/8/2016 11:00

Hybridan have 2.12p this year and 2.2p for 2017. I would have thought next year's forecast was a bit modest. I imagine another acquisition is quite on the cards. As I have close to 2% of this company I am with you guys on this one!